Infection can be catastrophic

ETHICON
PART OF THE Johnson&Johnson FAMILY OF COMPANIES

Protect your **patients.**

Antibacterial protection that starts on the inside:

PLUS Antibacterial Sutures have been shown in vitro to inhibit bacterial colonization of the suture for 7 days or more and are effective against the most common organisms associated with SSIs[1-3]:

- ✔ Staphylococcus aureus
- ✔ Staphylococcus epidermidis
- ✔ Escherichia coli*
- ✔ K pneumoniae*
- ✔ MRSE
- ✔ MRSA



The petri dish image is for illustrative purposes only; zone of inhibition testing results can vary.

You've got **options.**

Stratafix™ Knotless Tissue Control Devices with Plus Antibacterial Technology



Scan to learn more

Dermabond™ Prineo™ Skin Closure System

Scan to learn more

- ✔ **Self-anchoring** technology maintains closure without knots, **eliminating knot-related complications**[4]
- ✔ STRATAFIX™ Symmetric PDS™ Plus provides **greater holding strength** than traditional sutures and can be used to **close in high-tension areas**, such as fascia[**5-10]
- ✔ Can **close wounds** substantially **faster** than using an interrupted technique[11]
- ✔ Provides a **flexible microbial barrier** with **99% protection** in vitro for 72 hours against organisms commonly responsible for SSIs[***12]
- ✔ May allow for **easy remote observation** of the incision due to its **transparent barrier**[† 13-14]
- ✔ While sutures and staples penetrate the skin and place tension on the wounded tissue, DERMABOND™ PRINEO™ Skin Closure System **redistributes tension in a uniform way**[#15]
- ✔ **No postsurgical dressings** may mean easier self-care for patients[16]

For complete indications, contraindications, warnings, precautions and adverse reactions, please reference full instructions for use.

*PDS™ Plus Antibacterial (polydioxanone) Suture and MONOCRYL™ Plus Antibacterial (poliglecaprone 25) Suture only. **Conclusions derived from pre-clinical data. ***Staphylococcus epidermidis, Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Enterococcus faecium. † conducted via video-conference or patient submitting photograph to discuss with HCP via teleconference. # Study performed ex vivo using porcine skin. **1.** Ming X, Rothenburger S, Yang D. In vitro antibacterial efficacy of Monocryl Plus Antibacterial Suture (poliglecaprone 25 with triclosan). Surg Infect (Larchmt). 2007;8(2):201-207. **2.** Rothenburger S, Spangler D, Bhende S, Burkley D. In vitro antimicrobial evaluation of Coated VICRYL* Plus Antibacterial Suture (coated polyglactin 910 with triclosan) using zone of inhibition assays. Surg Infect (Larchmt). 2002;3(suppl 1):S79-S87. **3.** Ming X, Rothenburger S, Nichols MM. In vivo in vitro antibacterial efficacy of PDS* Plus (polydioxanone with Triclosan) Suture. Surg Infect (Larchmt). 2008;9(4):451-457. **4.** Ethicon, LAB100028658v3 STRATAFIX Knotless Tissue Control Device. Instructions for Use. Data on File. **5.** Ethicon, 100326296 Time Zero Tissue Holding - Competitive Claims Comparisons for STRATAFIX™ Knotless Tissue Control Devices vs Various Products. May 2015. Data on File. **6.** Ethicon, AST-2011-0210. Study to evaluate the tissue holding performance at time zero of DOLFIN PDS™ PLUS barbed suture sizes 1 and 2-0 vs dyed PDS™ II Plus suture sizes 1 and 2-0 in a continuous stitch pattern—Project DOLFIN 11822. July 2011. Data on File. **7.** Ethicon, AST-2011-0341. Performance testing of DOLFIN PDS™ PLUS size 3-0 suture—tissue holding 10 cm incision. August, 2011. Data on File. **8.** Ethicon, PSE 09-0204, project number 11822. Exploratory histological and biomechanical evaluation of DOLFIN following closure of the ventral abdominal wall in a porcine model at 7+/-1 days. July 2010. Data on File. **9.** Ethicon, PSE 10-0012, project number 11822. Model development: histological and biomechanical evaluation of 3-0 DOLFIN barbed suture prototypes, 3-0 Quill suture, and 3-0 V-loc suture at 7+/-1 days following closure of the ventral abdominal wall in a rabbit model. August 2011. Data on File. **10.** Ethicon, AST-2013-0603. Performance Testing of STRATAFIX™ SYMMETRIC PDS™ PLUS Size 0 & 1 Devices – Initiation Strength in Porcine Tissue. April 2014. Data on File. **11.** Greenberg J, Goldman R. Barbed Suture: A Review of the Technology and Clinical Uses in Obstetrics and Gynecology. Rev Obstet Gynecol. 2013;6(3-4):107-115. **12.** Ethicon, 06TR071 Study Report for in vitro evaluation of microbial barrier properties of DERMABOND™ ProTape, December 2006, Data on File. **13.** Ethicon, 20210201 Transparency of DERMABOND PRINEO R&D Memo. February, 2021. Data on File. **14.** Ethicon, LAB 0013100 Rev 6 - DERMABOND™ PRINEO™ Skin Closure System Instructions for Use Package Insert. Jan 2020. Data on File **15.** Ethicon, 100216627 Report for mapping strains in DERMABOND™ PRINEO™ Skin Closure System 22 cm (DP22) Comparative Study, August 2014, Data on File. **16.** De Cock E, van Nooten F, Mueller K, Tan R. Changing the surgical wound closure management pathway: time and supplies with PRINEO vs. standard of care for abdominoplasty surgery in Germany. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research, 11th Annual European Congress: November 2008; Athens, Greece. (142179-200603).

ETHICON

PART OF THE Johnson & Johnson FAMILY OF COMPANIES

Johnson & Johnson Medical Limited, Baird House, 4 Lower Gilmore Bank, Edinburgh, EH3 9QP, UK